RxDoctor Payments Data

Stephen Siegel, MD

Urology · Boulder, CONPI 1902860091

Payments from drug & device makers

$7,343in general payments, 2019–2025

Across 188 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$3K
  • Teleflex LLC$2K
  • Boston Scientific$417
  • Sumitomo Pharma America, Inc.$406
  • Neotract Inc.$339
  • Astellas Pharma US Inc$295
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$2,11929%
  • Food & beverage$5,00968%
  • Education$2163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,343 in reported general payments places this provider in the 70th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$440,998
Medicare patients
688
Services billed
10,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron162$147,985
GemtesaVibegron106$95,941
OrgovyxRelugolix24$64,832
Potassium Citrate ErPotassium Citrate13$5,695
Tamsulosin Hcl299$3,949
Solifenacin Succinate64$2,798
Alfuzosin Hcl ErAlfuzosin Hcl78$1,837
Testosterone31$1,784
Silodosin23$1,169
Methenamine Hippurate12$1,003
Finasteride60$885
Dutasteride23$691
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim89$270
Cephalexin41$224
Oxybutynin Chloride ErOxybutynin Chloride21$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$406$160,773130 claims
Astellas Pharma US IncMyrbetriq$295$147,985162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 urology providers in Colorado.

Other urology in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →